Clinical Trials Logo

Generalized Anxiety Disorder clinical trials

View clinical trials related to Generalized Anxiety Disorder.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05306977 Terminated - Clinical trials for Generalized Anxiety Disorder

rTMS Pilot for Anxiety

Start date: May 19, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of 1 Hz parietal stimulation in anxiety. Our approach will be to administer 1 week of open-label accelerated 1 Hz parietal rTMS (5 days, 8 sessions/day, 600 pulses/session) and measure the effect of this neuromodulation on APS, and short term memory in a cohort of anxiety GAD patients.

NCT ID: NCT04901481 Terminated - Clinical trials for Generalized Anxiety Disorder

Empower Neuromodulation System - Pilot Study for Anxiety Treatment

Start date: September 17, 2021
Phase: N/A
Study type: Interventional

This study evaluates the effects of peripheral nerve stimulation on anxiety levels in participants with Generalized Anxiety Disorder (GAD). This is a pilot investigation in which participants will randomized (1:1) to the active or sham treatment.

NCT ID: NCT04714164 Terminated - Clinical trials for Major Depressive Disorder

Cognitive Behavioral Therapy Group for Older Adults Delivered by Telethealth

Start date: February 18, 2021
Phase: N/A
Study type: Interventional

The present aim of the study is to to adapt an established, manualized enhanced Group CBT (CBT-E) for seniors to a telehealth format, which will allow us to offer the group virtually during the COVID-19 pandemic.

NCT ID: NCT04274114 Terminated - Clinical trials for Generalized Anxiety Disorder

Treatment of Adults With Generalized Anxiety Disorder Using Glutamine

Start date: January 18, 2019
Phase: Phase 2
Study type: Interventional

The objective of this randomized clinical trial is to examine the efficacy of L-glutamine for the treatment of generalized anxiety disorder compared versus placebo.

NCT ID: NCT03764644 Terminated - Clinical trials for Generalized Anxiety Disorder

Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders

ATTENTIO
Start date: October 2013
Phase: N/A
Study type: Interventional

Anxiety disorders are the most common childhood psychiatric disorders, with prevalence rates as high as 15% to 20%. Success rates of the first choice treatment strategy (i.e. Cognitive Behavioural Therapy; CBT) are around 50%. Non-response increases the risk for other psychiatric disorders, school dropout, social isolation, alcoholism, and suicide attempts. These negative consequences endorse the urgent need to develop more effective and accessible treatments that enhance effectiveness of current treatment options. A promising new treatment for childhood anxiety disorders is Attention Bias Modification Treatment (ABMT). ABMT is based on evidence that anxiety-disordered individuals selectively allocate their attention toward threatening information (i.e. attention bias). This bias in early and automatic attention processes starts a cascade of subsequent biases in information processing and memory, resulting in heightened anxiety. Attention bias is an underlying mechanism of anxiety. Thus ABMT, which implicitly trains individuals to attend away from threatening information should alleviate anxiety. In contrast to ABMT, CBT explicitly targets later stages of information processing that are under volitional control. Meta-analyses of studies in adults have shown that ABMT indeed results in increased recovery rates and clinically significant changes in anxiety, compared to so-called "sham" attention training (control condition). Imaging studies have shown that ABMT modifies lateral prefrontal cortex activity to emotional stimuli. Despite its promising results, fewer studies have examined ABMT in anxiety-disordered children. The aim of this trial is to enhance treatment effectiveness by combining web-based ABMT with CBT in a large sample of anxiety-disordered children. The primary aim is to compare ABMT-augmented CBT with CBT as monotherapy on recovery rates for anxiety disorders and changes in anxiety. The secondary aim is to compare ABMT with sham attention training on anxiety disorder recovery rates and changes in anxiety. We hypothesize that (1) ABMT-augmented CBT will result in a significantly better treatment success than CBT alone, and (2) ABMT will result in a significantly better treatment success than sham attention training. The design will be a randomized, double-blind, sham-controlled clinical trial.

NCT ID: NCT03463018 Terminated - Clinical trials for Generalized Anxiety Disorder

Echinacea Angustifolia (AnxioCalm) in Anxiety

Start date: June 6, 2018
Phase: Phase 2
Study type: Interventional

This study evaluates whether Echinacea angustifolia (AnxioCalm) is a safe and effective treatment for mild to moderate Generalized Anxiety Disorder (GAD) symptoms. Half the participants will receive Echinacea angustifolia and half will receive placebo.

NCT ID: NCT03420456 Terminated - Clinical trials for Generalized Anxiety Disorder

Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study

Lighten-GAD
Start date: September 24, 2018
Phase: N/A
Study type: Interventional

Transcranial Light Therapy involves non-invasive and invisible beams of light that increase energy metabolism in the brain. Transcranial light therapy has been found to promote brain metabolism which may help people with anxiety. The research team proposes a novel approach to treating anxiety by using transcranial light therapy.

NCT ID: NCT02572973 Terminated - Clinical trials for Generalized Anxiety Disorder

Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders

ANM
Start date: July 2014
Phase: N/A
Study type: Interventional

The acoustic neuromodulation trial (ANM-T) is a two-phase, single-site, pilot randomized clinical trial examining the feasibility of completing a larger scale efficacy study of a novel treatment of non-linear modulated acoustic stimuli to reduce anxiety severity in youth with anxiety disorders. The primary objective is to establish the feasibility of a blinded randomized controlled trial of ANM for childhood anxiety disorders.

NCT ID: NCT02310568 Terminated - Clinical trials for Generalized Anxiety Disorder

POC Study in Partially Responsive Generalized Anxiety Disorder

Start date: November 2014
Phase: Phase 2
Study type: Interventional

This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (HAM-A) to measure change in symptoms from baseline for two doses of PF-06372865 compared to placebo.

NCT ID: NCT02189213 Terminated - Clinical trials for Generalized Anxiety Disorder

Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep

Start date: July 2014
Phase: N/A
Study type: Interventional

1 out of 8 children, adolescents, and young adults suffer from an anxiety disorder. Studies over the past decade show that selective serotonin-reuptake inhibitors (SSRIs), a class of medication that treats anxiety in adults, also works well in young adults, children, and adolescents with anxiety disorders, but only for about 50%. 50% will have undergone treatment for several months before it will be established that the medication is not working to treat the anxiety. The purpose of this study is to find a test that will predict treatment outcome from the beginning based on behavioral and biological measures.